News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Roche Diagnostics Corporation (ROG.VX) Named to FORTUNE Magazine's 2013 List of "100 Best Companies to Work for"


1/17/2013 10:23:14 AM

INDIANAPOLIS, Jan. 17, 2013 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche Diagnostics Corporation has been selected to FORTUNE magazine's annual list of the "100 Best Companies to Work For." Roche debuted at 89 on the list and is the only Indiana-based company selected.

(Photo: http://photos.prnewswire.com/prnh/20130117/DE44332 )

"Being named a 'Best Company to Work For' validates what we already know about our organization," said Jack Phillips, president and CEO of Roche Diagnostics. "Roche is not only a leader in personalized healthcare; we're also a leader in attracting and developing the best people. We are successful only because our people are successful and I couldn't be prouder that our entire workforce is being recognized by this award."

In selecting Roche Diagnostics for the list, Fortune magazine cited the company's on-site medical clinic and fitness center; $30,000 budget for intramural sports; and health insurance plans tiered to income levels.

The entire list of the 2013 "100 Best Companies to Work For" is available at www.fortune.com/bestcompanies.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com or www.roche-diagnostics.us.

All trademarks used or mentioned in this release are protected by law.

For further information, please contact:

Todd Siesky
Director, Corporate Communications
Roche Diagnostics Corporation
Indianapolis, IN
(317) 521-3966
todd.siesky@roche.com

SOURCE Roche Diagnostics


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES